Statin-Associated Muscle Adverse Events Update for clinicians

Apply

Statin-Associated Muscle Adverse Events Update for clinicians

Journal Title: Sultan Qaboos University Medical Journal - Year 2016, Vol 16, Issue 4

Abstract

Statins are potent medications which reduce low-density lipoprotein cholesterol (LDL-C) levels. Teir efcacy in cardiovascular risk reduction is well established and indications for their use are expanding. While statins are generally well tolerated and safe, adverse events are relatively common, particularly statinassociated muscle adverse events (SaMAEs), which are the most frequently encountered type of adverse event. Recent guidelines and guideline updates on SaMAEs and statin intolerance have included revised defnitions of SaMAEs, incorporating new evidence on their pathogenesis and management. As SaMAEs emerge as a therapeutic challenge, it is important for physicians to be aware of updates on management strategies to ensure better patient outcomes. Te majority of patients who are considered statin-intolerant can nevertheless tolerate some forms of statin therapy and successfully achieve optimal LDL-C levels. Tis review article discusses the recent classifcation of SaMAEs with emphasis on pathogenesis and management strategies.

Authors and Affiliations

Maha A. Al-Mohaissen| Department of Clinical Sciences, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia, Martha J. Ignaszewski| Department of Psychiatry, Baystate Medical Center, Tufts University School of Medicine, Springfeld, Massachusetts, USA, Jiri Frohlich| Departments of Pathology & Laboratory Medicine and Cardiology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada, Andrew P. Ignaszewski| Departments of Cardiology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Keywords

EP ID EP14710
DOI -
Views 259
Downloads 14